Results overview: Found 3 records in 0.01 seconds.
Articles, 3 records found
Articles 3 records found  
1.
13 p, 5.3 MB BET inhibition is an effective approach against KRAS-driven PDAC and NSCLC / Jauset, Toni (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ; Massó Vallés, Daniel (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ; Martínez Martín, Sandra (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ; Beaulieu, Marie-Eve (Vall d'Hebron Institut d'Oncologia) ; Foradada, Laia (Vall d'Hebron Institut d'Oncologia) ; Fiorentino, Francesco Paolo (Department of Biomedical Sciences, University of Sassari) ; Yokota, Jun (Institut d'Investigació Germans Trias I Pujol) ; Haendler, Bernard (Drug Discovery, Bayer AG) ; Siegel, Stephan (Drug Discovery, Bayer AG) ; Whitfield, Jonathan R. (Vall d'Hebron Institut d'Oncologia) ; Soucek, Laura (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular)
Effectively treating KRAS-driven tumors remains an unsolved challenge. The inhibition of downstream signaling effectors is a way of overcoming the issue of direct targeting of mutant KRAS, which has shown limited efficacy so far. [...]
2018 - 10.18632/oncotarget.24648
Oncotarget, Vol. 9 (april 2018) , p. 18734-18746  
2.
13 p, 1.2 MB Strategies to Inhibit Myc and Their Clinical Applicability / Whitfield, Jonathan R. (Vall d'Hebron Institut d'Oncologia) ; Beaulieu, Marie-Eve (Hospital Universitari Vall d'Hebron) ; Soucek, Laura (Universitat Autònoma de Barcelona. Departament de Bioquímica i Biologia Molecular)
Myc is an oncogene deregulated in most—perhaps all—human cancers. Each Myc family member, c-, L-, and N-Myc, has been connected to tumor progression and maintenance. Myc is recognized as a "most wanted" target for cancer therapy, but has for many years been considered undruggable, mainly due to its nuclear localization, lack of a defined ligand binding site, and physiological function essential to the maintenance of normal tissues. [...]
2017 - 10.3389/fcell.2017.00010
Frontiers in Cell and Developmental Biology, Vol. 5 (February 2017) , art. 10  
3.
11 p, 1.8 MB Myc inhibition is effective against glioma and reveals a role for Myc in proficient mitosis / Annibali, Daniela (University of California) ; Whitfield, Jonathan R. (Vall d'Hebron Institut d'Oncologia) ; Favuzzi, Emilia (Università La Sapienza) ; Jauset, Toni (Universitat Autònoma de Barcelona) ; Serrano, Erika (Universitat Autònoma de Barcelona) ; Cuartas, Isabel (Universitat Autònoma de Barcelona) ; Redondo Campos, Sara (Universitat Autònoma de Barcelona) ; Folch, Gerard (Universitat Autònoma de Barcelona) ; Gonzàlez Juncà, Alba (Universitat Autònoma de Barcelona) ; Sodir, Nicole M. (University of Cambridge) ; Massó Vallés, Daniel (Universitat Autònoma de Barcelona) ; Beaulieu, Marie-Eve (Universitat Autònoma de Barcelona) ; Swigart, Lamorna B. (University of California) ; Mc Gee, Margaret M. (University College Dublin) ; Somma, Maria Patrizia (Università La Sapienza) ; Nasi, Sergio (Università La Sapienza) ; Seoane Suárez, Joan (Institució Catalana de Recerca i Estudis Avançats (ICREA)) ; Evan, Gerard I. (University of Cambridge) ; Soucek, Laura (Universitat Autònoma de Barcelona)
Gliomas are the most common primary tumours affecting the adult central nervous system and respond poorly to standard therapy. Myc is causally implicated in most human tumours and the majority of glioblastomas have elevated Myc levels. [...]
2014 - 10.1038/ncomms5632
Nature Communications, Vol. 5 (August 2014) , art. 4632  

Interested in being notified about new results for this query?
Set up a personal email alert or subscribe to the RSS feed.